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Abstract
Background: Cell surface NKG2D ligands (NKG2DL) bind to the activating NKG2D receptor present on NK cells and
subsets of T cells, thus playing a role in initiating an immune response. We examined tumor expression and
prognostic effect of NKG2DL in breast cancer patients.
Methods: Our study population (n = 677) consisted of all breast cancer patients primarily treated with surgery in
our center between 1985 and 1994. Formalin-fixed paraffin-embedded tumor tissue was immunohistochemically
stained with antibodies directed against MIC-A/MIC-B (MIC-AB), ULBP-1, ULBP-2, ULBP-3, ULBP-4, and ULBP-5.
Results: NKG2DL were frequently expressed by tumors (MIC-AB, 50% of the cases; ULBP-1, 90%; ULBP-2, 99%;
ULBP-3, 100%; ULBP-4, 26%; ULBP-5, 90%) and often showed co-expression: MIC-AB and ULBP-4 (p = 0.043), ULBP-1
and ULBP-5 (p = 0.006), ULBP-4 and ULBP-5 (p < 0.001). MIC-AB (p = 0.001) and ULBP-2 (p = 0.006) expression
resulted in a statistically significant longer relapse free period (RFP). Combined expression of these ligands showed
to be an independent prognostic parameter for RFP (p < 0.001, HR 0.41). Combined expression of all ligands
showed no associations with clinical outcome.
Conclusions: We demonstrated for the first time that NKG2DL are frequently expressed and often co-expressed in
breast cancer. Expression of MIC-AB and ULBP-2 resulted in a statistically significant beneficial outcome concerning
RFP with high discriminative power. Combination of all NKG2DL showed no additive or interactive effect of ligands
on each other, suggesting that similar and co-operative functioning of all NKG2DL can not be assumed. Our
observations suggest that among driving forces in breast cancer outcome are immune activation on one site and
tumor immune escape on the other site.
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Background
Breast cancer is the most commonly diagnosed female
cancer and is the leading cause of death from cancer in
women in the western world [1]. Decisions regarding
use of systemic therapy are mainly based on prognostic
and predictive factors like lymph node status, tumor
size, grade, hormone receptor and human epidermal
growth factor receptor 2 (HER2) expression [2,3]. How-
ever, current prognostic and predictive factors still do
not provide optimal risk-stratification. Therefore, addi-
tional prognostic and predictive information could result
in an improved tailored treatment for patients with
breast cancer.
There is strong evidence that the immune system
plays a role in tumor growth and progression [4,5]. An
effective immune response may lead to recognition of
tumor cells, resulting in their eradication. However, due
to their genetic unstable nature, tumor cells may arise
which display properties that enables them to escape
from immune recognition [4,5]. Indeed, downregulation
or loss of proteins that are crucial for immune
responses, like classical human leukocyte antigens
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(HLA) class I, or upregulation of proteins that confer
resistance to immune recognition, like non-classical
HLA class I, are frequently found in various types of
tumors [6-10].
The activating receptor natural killer cell lec-tin-like
receptor gene 2D (NKG2D) is a stimulatory immune
receptor that is expressed on natural killer (NK) cells,
NKT cells, gδ+ T cells and CD8+ T cells [11]. Ligands
which bind NKG2D receptors comprise major histo-
compatibility complex class I chain-related proteins A
and B (MIC-AB) and unique long 16 (UL16) binding
proteins 1-6 (ULBP1-6) [12,13]. Expression of these
ligands may be induced upon infection and other indu-
cers of cellular stress and is unusual in normal cells
[14]. By binding to the NKG2D receptors on NK and T
cells, the NKG2D ligands may initiate an immune
response against cells expressing these ligands. Overex-
pression and shedding of NKG2D ligands have been
reported [14]. It is, however, unclear whether these fea-
tures also results in activation of an immune response
or lead to overstimulation and downregulation of
NKG2D on immune cells [11].
Malignant transformation of cells may be among sti-
muli inducing expression of NKG2D ligands as such
expression has been found in various tumor types
[8-10,15-18]. This may be a mechanism for preventing
tumor growth by advancing an anti-tumor immune
response. Convincing evidence has been found in in vivo
studies, which have shown that in mouse models trans-
fection with NKG2D ligands resulted in a NKG2D-
mediated tumor rejection [19,20]. Other studies showed
that downregulation or complete knockout of NKG2D
in mice resulted in an impaired immune response
against tumor cells, higher expression levels of NKG2D
ligands, and an increased incidence of certain tumors
[21,22].
A few studies have investigated tumor expression of
NKG2D ligands and associations with clinical outcome
in human breast, colorectal, and ovarian cancer
[8-10,15,16]. Expression of MIC-A was frequently found
in all tumors studied and resulted in a statistically sig-
nificant favorable patient’s prognosis in colorectal can-
cer, while it was not statistically significantly associated
with outcome in breast cancer and ovarian cancer
[8-10,16]. ULBP1-5 expression was also found to be
expressed in many tumor samples of colorectal and
ovarian cancer [9,10,15]. In colorectal cancer expression
of ULBP5 was an independent prognostic factor for a
favorable clinical outcome [9]. In contrast to these
results, expression of ULBP2 and ULBP4 were found to
be independent prognostic factors for a worse outcome
of ovarian cancer patients [10,15]. Taken together, sev-
eral studies suggest that evasion of NKG2D-mediated
immune regulation plays an important role in tumor
progression, but some studies contradict this suggestion.
Contradictory results may be explained by assuming
functional differences in immune regulation of the dif-
ferent ligands. Moreover, expression of NKG2D ligands
may behave different among different tumor types [9]. It
is known that overexpression or shedding of these
ligands leads to overstimulation and downregulation of
NKG2D on immune cells [10,15], thereby evading an
immune response.
In breast cancer, the prognostic effect of NKG2D
ligands and their mutual relationship is largely
unknown. Therefore, the purpose of this study was to
analyze the clinical prognostic value of MIC-AB and
ULBP1-5 in a large patient cohort of early stage breast
cancer.
Methods
Patients and tumors
The patient population comprised all non-metastasized
breast cancer patients primarily treated with surgery
between 1985 and 1994 at the Leiden University Medi-
cal Center (n = 677). Patients with bilateral tumors or a
prior history of cancer, other than basal cell carcinoma
or cervical carcinoma in situ, were excluded. The fol-
lowing data were known: age, tumor morphology and
differentiation grade, TNM stage, type of local and sys-
temic therapy, recurrence and survival status, estrogen
receptor (ER), progesterone receptor (PgR), and human
epidermal growth factor 2 (HER2) expression (Table 1).
All these parameters were determined according to cur-
rent pathology standards. A tissue micro array (TMA)
of available formalin-fixed paraffin-embedded (FFPE)
tumors of the patient cohort has been previously con-
structed and described (n = 574) [23]. Approval was
obtained from the Leiden University Medical Center
Medical Ethics Committee. All samples were handled in
a coded fashion, according to National ethical guidelines
("Code for Proper Secondary Use of Human Tissue”,
Dutch Federation of Medical Scientific Societies).
Immunohistochemistry
Antibodies specific against MIC-AB (ab54413; Abcam),
ULBP-1 (HPA007547; Atlas antibodies), ULBP-2
(af1298; R&D systems), ULBP-3 (CUMO3-100; BAMO-
MAB), ULBP-4 (RAET1E) and ULBP-5 (RAET1G, both
kindly provided by Dr. Robert A Eagle, Cambridge, UK)
[9,24] were used for immunohistochemical staining of
tumor tissue. The specificity of anti-ULBP-2 antibody
has been previously determined, which showed occas-
sional cross-reactity with highly related molecules
RAET1L and to a lesser extent with RAET1G, but a
good recognition of ULBP-2 [25]. We are not aware of
antibodies which can specifically discriminate between
ULBP2, RAET1L and RAET1G extracellular domains.
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TMA sections of 4 μm were cut, deparaffinized and
rehydrated. Endogenous peroxidase was blocked in 0.3%
hydrogen-peroxide methanol for 20 minutes. Heat-
induced antigen retrieval for 10 minutes at maximum
power in a microwave oven was performed. Sections
were incubated overnight with primary antibodies using
predetermined optimal dilutions and incubations times.
Sections for ULBP-2 staining were incubated with Rab-
bit Anti-Goat Immunoglobulins (DAKO) followed by
StreptABComplex (DAKO) for 30 minutes. Sections for
all other stainings were incubated with secondary
antibody Envision (Dako cytomation K4001 or K4003)
for 30 minutes. Stainings were visualized using DAB-
solution (Dako cytomation K3468), counterstained with
haematoxylin, dehydrated, and finally mounted in mali-
nol. For each type of antibody, all tissue sections were
stained simultaneously to avoid inter-assay variation.
Evaluation of immunostaining
Microscopic analysis of MIC-AB, ULBP-1, ULBP-2,
ULBP-3, ULBP-4 and ULBP-5 expression was performed
by two independent observers in a blinded manner.
Table 1 Correlations between MIC-A-B, ULBP-1, ULBP-2 expression and well-established prognostic factors.
Total MICAB ULBP1 ULBP2
Low High Low High Low High
N % N % N % N % N % N % N %
Age
< 40
40-50
50-60
> = 60
48
145
132
249
8.4
25.3
23.0
43.4
4
28
26
42
4.0
28.0
26.0
42.0
31
86
78
163
8.7
24.0
21.8
45.5
22
62
45
91
10.0
28.2
20.5
41.4
10
32
44
79
6.1
19.4
26.7
47.9
34
85
100
172
8.7
21.7
25.6
44.0
9
42
20
52
7.3
34.1
16.3
42.3
Grade
I
II
III
80
282
203
14.2
49.9
35.9
22
42
36
22.0
42.0
36.0
38
181
131
10.9
51.7
37.4
39
109
68
18.1
50.5
31.5
9
80
74
5.5
49.1
45.4
41
188
155
10.7
49.0
40.4
27
65
30
22.1
53.3
24.6
Histological type
Ductal
Lobular
513
53
90.6
9.4
91
9
91.0
9.0
322
29
91.7
8.3
194
22
89.8
10.2
151
12
92.6
7.4
354
30
92.2
7.8
106
16
86.9
13.1
T-status
T1
T2
T3/4
211
272
72
38.0
49.0
13.0
40
44
12
41.7
45.8
12.5
124
176
47
35.7
50.7
13.5
96
87
31
44.9
40.7
14.5
37
96
26
23.3
60.4
16.4
128
198
54
33.7
52.1
14.2
59
46
12
50.4
39.3
10.3
N-status
N0
N1-3
307
250
55.1
44.9
60
38
61.2
38.8
181
162
52.8
47.2
118
97
54.9
45.1
69
86
44.5
55.5
196
183
51.7
48.3
74
45
62.2
37.8
ER-status
Negative
Positive
203
337
37.6
62.4
33
65
33.7
66.3
137
212
39.3
60.7
95
122
43.8
56.2
55
103
34.8
65.2
147
238
38.2
61.8
45
75
37.5
62.5
PgR-status
Negative
Positive
223
313
41.6
58.4
33
66
33.3
66.7
147
198
42.6
57.4
88
127
40.9
59.1
68
90
43.0
57.0
169
217
43.8
56.2
40
78
33.9
66.1
Her2-status
No overexpression-
Overexpression
378
44
89.6
10.4
78
6
92.9
7.1
264
36
88.0
12.0
174
20
89.7
10.3
125
15
89.3
10.7
291
29
90.9
9.1
79
14
84.9
15.1
Local Therapy
MAST-RT
MAST+RT
BCS-RT
BCS+RT
223
108
5
238
38.9
18.8
0.9
41.5
41
17
0
42
41.0
17.0
0.0
42.0
146
66
5
141
40.8
18.4
1.4
39.4
80
46
2
92
36.4
20.9
0.9
41.8
79
33
2
51
47.9
20.0
1.2
30.9
149
83
5
154
38.1
21.2
1.3
39.4
53
15
0
55
43.1
12.2
0.0
44.7
Systemic therapy
CT alone
HT alone
CT&HT
None
112
75
18
369
19.5
13.1
3.1
64.3
17
8
1
74
17.0
8.0
1.0
74.0
73
54
13
218
20.4
15.1
3.6
60.9
44
31
3
142
20.0
14.1
1.4
64.5
25
29
9
102
15.2
17.6
5.5
61.8
80
54
14
243
20.5
13.8
3.6
62.1
24
16
3
80
19.5
13.0
2.4
65.0
Total 574 100 100 100 358 100 220 100 165 100 391 100 123 100
Missing values are not shown.
Abbreviations N number of patients; % percentage; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST
mastectomy; RT radiotherapy; BCS breast conservative surgery; ET endocrine therapy; CT chemotherapy.
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Since staining of tumors was relatively homogenous, for
each tumor the overall intensity of staining (negative
(0), weak (1), intermediate (2) or strong (3)) was
determined.
Statistical analysis
Statistical analyses were performed using the statistical
package SPSS (version 16.0 for Windows, Spps Inc, Chi-
cago, IL, USA). Cohen’s kappa coefficient was used to
assess inter-observer agreement in quantification. This
revealed a moderate agreement for ULBP-5 (kappa =
0.410), a substantial agreement in classification for MIC-
AB (kappa = 0.790) and ULBP-4 (kappa = 0.650), and an
almost perfect agreement for ULBP-1 (kappa = 0.913),
ULBP-2 (kappa = 0.940), and ULBP-3 (kappa = 0.869).
The c2 test was used to evaluate associations between
expression of the different NKG2D ligands. Relapse free
period (RFP) was the time from date of surgery until an
event (locoregional recurrence and/or a distance recur-
rence, whichever came first). The Kaplan-Meier method
was used for survival plotting and log-rank test for com-
parison of survival curves. RFP is reported as cumulative
incidence function, after accounting for death as com-
peting risk [26]. Cox regression was used for univariate
and multivariate analysis for RFP. Significant variables
(p < 0.1) in univariate analysis were included in multi-
variate analysis.
Results
Patient and tumor characteristics
Median age of patients was 57 years (range: 23-96
years). Median follow-up of patients alive was 19 years
(range: 14-23 years). Clinicopathological and treatment
characteristics are shown in table 1.
Expression of NKG2D ligands
Most of the NKG2D ligands examined in this study
were frequently expressed among the breast tumor
cohort: MIC-AB in 50% of the cases; ULBP-1 in 90%;
ULBP-2 in 99%; ULBP-3 in 100%; ULBP-4 in 26%; and
ULBP-5 in 90%. A broad distribution of immunohisto-
chemical staining-intensities was seen for ULBP-2,
ULBP-3 and ULBP-5, while MIC-AB, ULBP-1 and
ULBP-4 showed a skewed distribution of staining-inten-
sities where most tumors stained weakly positive (repre-
sentative examples of staining: Figure 1). Therefore, the
median intensity was taken as a cut-off value for all
ligands to categorize low and high expression resulting
in respectively 50%, 43%, 24%, 27%, 26%, 10% of tumors
with high expression of MIC-AB (Figure 1B), ULBP-1
(Figure 1D), ULBP-2 (Figure 1F), ULBP-3 (Figure 1H),
ULBP-4 (Figure 1J) and ULBP-5 (Figure 1L) and respec-
tively 50%, 57%, 76%, 73%, 90% of the tumors with low
expression of MIC-AB (Figure 1A), ULBP-1 (Figure 1C),
ULBP-2 (Figure 1E), ULBP-3 (Figure 1G), ULBP-4 (Fig-
ure 1I) and ULBP-5 (Figure 1K).
NKG2D ligands were found to be frequently co-
expressed: MIC-AB positively correlated with ULBP-4 (p
= 0.043); ULBP-1 showed a positive correlation with
ULBP-5 (p = 0.006); ULBP-4 had a positive correlation
with ULBP-5 (p < 0.001).
Association of NKG2D ligands with clinicopathological
parameters
High expression of NKG2D ligands was generally asso-
ciated with favorable clinicopathological parameters
(table 1 and 2): statistically significant associations were
found between high expression of MIC-AB and lower
tumor grade (p = 0.012); high expression of ULBP-1 and
higher tumor grade (p < 0.001), smaller tumor size (p <
0.001) and more lymph node positive tumors (p = 0.049);
high expression of ULBP-2 and younger age (p = 0.022),
lower tumor grade (p < 0.001), smaller tumor size (p =
0.005) and more lymph node negative tumors (p =
0.046); high expression of ULBP-3 and higher tumor
grade (p = 0.001); high expression of ULBP-4 and smaller
tumor size (p = 0.001); high expression of ULBP-5 and
more PgR negative tumor status (p = 0.016).
Associations with outcome of NKG2D ligands
When analyzed separately, MIC-AB and ULBP-2
showed statistically significant results on outcome ana-
lyses (log rank p-values respectively: 0.001, 0.006), where
high expression of MIC-AB and ULBP-2 showed to
have fewer relapses over time compared to low expres-
sion (Figure 2A, C). For MIC-AB low expression, 51% of
patients were relapse free after 20 years, while of
patients with high expression of MIC-AB 27% showed a
relapse within 20 years. For ULBP-2, 20 year RFP rates
for low expression versus high expression were respec-
tively 56% and 43%. No statistically significant associa-
tions with outcome were seen for ULBP-1, ULBP-3,
ULBP-4 and ULBP-5 (Figure 2B, D-F).
Cox univariate regression analysis was performed for
expression of each type of ligand. MIC-AB (Hazard ratio
(HR) 0.60, 95% confidence interval (95%CI) 0.448-0.810,
p = 0.001) and ULBP-2 (HR 0.63, 95%CI 0.454-0.869, p
= 0.005) showed statistically significant results for a
favorable RFP, while all other types of ligands did not
reach statistical significance (data not shown).
To seek how combined expression of MIC-AB and
ULBP2 ligands would predict patient outcome a new
variable was made representing expression of both
ligands: (1) Both MIC-AB and ULBP-2 low expression;
(2) either MIC-AB or ULBP-2 high expression; (3) both
MIC-AB and ULBP-2 high expression. Combined
expression of MIC-AB and ULBP-2 resulted in a prog-
nostic factor (log rank p-value: < 0.001; Figure 3), where
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Figure 1 Representative examples of immunohistochemical stainings of primary breast cancer tissues for respectively no expression
and high expression of MIC-AB (A: intensity 0 (negative); B: intensity 2 (intermediate)), ULBP-1 (C: intensity 0 (negative); D: intensity 2
(intermediate)), ULBP-2 (E: intensity 0 (negative); F: intensity 3 (strong)), ULBP-3 (G: intensity 0 (negative); H: intensity 3 (strong)),
ULBP-4 (I: intensity 0 (negative); J: intensity 1 (weak)), and ULBP-5 (K: intensity 0 (negative); L: intensity 3 (strong)) in breast cancer.
Immunohistochemistry was performed according to standard protocols as described in Materials and Methods.
de Kruijf et al. BMC Cancer 2012, 12:24
http://www.biomedcentral.com/1471-2407/12/24
Page 5 of 20
low expression of both ligands versus high expression of
either ligand versus high expression of both ligands
resulted in respectively 23%, 48% and 60% of patients to
be relapse free after 20 years. Cox proportional multi-
variate analysis showed the combined ligand variable to
be statistically significant for RFP independently of
known clinicopathological parameters (MIC-AB and
ULBP-2 both low versus either high: HR 0.54, 95%CI
0.380-0.757; MIC-AB and ULBP-2 both low versus both
high: HR 0.41, 95%CI 0.246-0.682; p-value < 0.001)
(Table 3).
In order to analyze the frequencies and prognostic
effect of number of co-expressed and amount of co-
expression of NKG2D ligands, two new variables were
constructed. First, the total number of the different
NKG2D ligands that were expressed. For that purpose,
the number of NKG2D ligands with high expression was
counted. So for each tumor, this resulted in a minimal
and maximal possible score of respectively 0 and 6. Sec-
ond, the total amount of NKG2D ligand expression. For
that purpose, the intensity of staining (ranging from 0
to 3) of NKG2D ligands was added, obtaining a total
Table 2 Correlations between ULBP-3, ULBP-4 and ULBP-5 expression and well-established prognostic factors.
Total ULBP3 ULBP4 ULBP5
Low High Low High Low High
N % N % N % N % N % N % N %
Age
< 40
40-50
50-60
> = 60
48
145
132
249
8.4
25.3
23.0
43.4
25
84
68
128
8.2
27.5
22.3
42.0
11
24
22
55
9.8
21.4
19.6
49.1
29
91
86
164
7.8
24.6
23.2
44.3
15
33
30
49
11.8
26.0
23.6
38.6
38
119
103
185
8.5
26.7
23.1
41.6
3
9
12
23
6.4
19.1
25.5
48.9
Grade
I
II
III
80
282
203
14.2
49.9
35.9
45
160
96
15.0
53.2
31.9
10
43
57
9.1
39.1
51.8
51
181
134
13.9
49.5
36.6
13
67
43
10.6
54.5
35.0
62
219
157
14.2
50.0
35.8
2
21
23
4.3
45.7
50.0
Histological type
Ductal
Lobular
513
53
90.6
9.4
281
20
93.4
6.6
102
8
92.7
7.3
330
37
89.9
10.1
113
10
91.9
8.1
396
43
90.2
9.8
43
3
93.5
6.5
T-status
T1
T2
T3/4
211
272
72
38.0
49.0
13.0
113
142
39
38.4
48.3
13.3
40
54
17
36.0
48.6
15.3
118
180
60
33.0
50.3
16.8
57
61
6
46.0
49.2
4.8
159
209
64
36.8
48.4
14.8
19
26
2
40.4
55.3
4.3
N-status
N0
N1-3
307
250
55.1
44.9
158
135
53.9
46.1
61
49
55.5
44.5
193
170
53.2
46.8
66
55
54.5
45.5
237
196
54.7
45.3
24
21
53.3
46.7
ER-status
Negative
Positive
203
337
37.6
62.4
113
178
38.8
61.2
37
73
33.6
66.4
135
222
37.8
62.2
43
80
35.0
65.0
152
278
35.3
64.7
21
25
45.7
54.3
PgR-status
Negative
Positive
223
313
41.6
58.4
130
159
45.0
55.0
42
68
38.2
61.8
141
215
39.6
60.4
51
72
41.5
58.5
158
267
37.2
62.8
26
21
55.3
44.7
Her2-status
Overexpression -
Overexpression +
378
44
80.9
19.1
207
24
89.6
10.4
82
10
89.1
10.9
256
33
88.6
11.4
93
6
93.9
6.1
311
32
90.7
9.3
35
6
85.4
14.6
Local Therapy
MAST-RT
MAST+RT
BCS-RT
BCS+RT
223
108
5
238
38.9
18.8
0.9
41.5
116
56
3
130
38.0
18.4
1.0
42.6
43
24
1
44
38.4
21.4
0.9
39.3
141
86
1
142
38.1
23.2
0.3
38.4
46
14
3
64
36.2
11.0
2.4
50.4
165
94
4
182
37.1
21.1
0.9
40.9
24
3
0
20
51.1
6.4
0.0
42.6
Systemic therapy
CT alone
HT alone
CT&HT
None
112
75
18
369
19.5
13.1
3.1
64.3
65
32
10
198
21.3
10.5
3.3
64.9
23
10
2
77
20.5
8.9
1.8
68.8
81
52
13
224
21.9
14.1
3.5
60.5
20
16
1
90
20.3
12.6
0.8
70.9
93
60
11
281
20.9
13.5
2.5
63.1
8
5
1
33
17.0
10.6
2.1
70.2
Total 574 100 305 100 112 100 370 100 127 100 445 100 47 100
Missing values are not shown.
Abbreviations N number of patients; % percentage; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST
mastectomy; RT radiotherapy; BCS breast conservative surgery; ET endocrine therapy; CT chemotherapy.
de Kruijf et al. BMC Cancer 2012, 12:24
http://www.biomedcentral.com/1471-2407/12/24
Page 6 of 20
NKG2D ligand intensity score. So for each tumor, this
resulted in a minimal and maximal possible score of
respectively 0 and 18.
The median number of NKG2D ligands with high
expression was 1 (range 0-6). For statistical reasons (too
small patient groups) in outcome analyses, the groups
with 3, 4, 5 and 6 numbers of different NKG2D ligands
highly expressed were combined as one single group: ≥
3 ligands of high expression.
No associations were seen for the number of NKG2D
ligands with high expression for RFP outcome analyses
(log rank p-value: 0.967); patients with tumors with a
low number of NKG2D ligands with high expression
resulted in a similar RFP compared to a high number of
NKG2D ligands with high expression (Figure 4A).
The median total amount of NKG2D ligand intensity
score was 8 (range 4-16). No tumors showed complete
lack (score 0) or high intensity expression of all NKG2D
ligands (score 18).
For outcome analyses, NKG2D scores 14-16 were
combined and classified as ≥ 14, since these subgroups
separately contained only one patient. No association
was seen for amount of total NKG2D ligand expression
and RFP (log rank p-value: 0.721); high total NKG2D
ligand expression resulted in some cases in a worse RFP
(e.g. score 11) while in others it resulted in a favorable
RFP (e.g. score 13) and vice versa, low total NKG2D
ligand expression resulted for some patients in a favor-
able RFP (e.g. score 6) and for other patients in a worse
RFP (e.g. score 4) (Figure 4B).
Discussion
The importance of interaction between tumor develop-
ment and the immune system for cancer outcome is
highlighted by an overwhelming number of studies, per-
formed in vitro, in vivo and using patient cohorts.
Recent studies have shown that NKG2D ligands may
play an important role in cancer immunosurveillance
and cancer immunoediting [8-10,15-22]. In this study,
we examined the impact of tumor expression of
NKG2D ligands on the prognosis of breast cancer
patients. The data of our study indicate that NKG2D
ligands are frequently high expressed in breast tumors
and that this expression influences prognosis of patients.
We were able to statistically prove that high expression
levels of MIC-AB and ULBP-2 resulted in a RFP benefit.
Combining expression of MIC-AB and ULBP-2 resulted
in a very accurate stratification of patients for prognosis
MICAB low
MICAB high
A 
ULBP1 low
ULBP1 high
B 
ULBP2 low
ULBP2 high
C 
ULBP3 low
ULBP3 high
D 
ULBP4 low
ULBP4 high
E 
ULBP5 low
ULBP5 high
F 
Figure 2 Relapses over time related with expression of MIC-AB (A), ULBP-1 (B), ULBP-2 (C), ULBP-3 (D), ULBP-4 (E), and ULBP-5 (F). X-
axis represents patient follow-up in years; Y-axis represents cumulative relapses in %. Log-rank p-values are shown in each graph. Only
expression of MIC-AB and ULBP-2 resulted in statistically significantly favorable relapse-free period (RFP).
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concerning RFP. The prognostic potential of this com-
bined variable was comparable to that of lymph node
status: patients with low tumor expression of both
ligands had an almost 2.5 times increased risk of devel-
oping relapses compared to patients with high tumor
expression of both ligands.
NKG2D ligands are expressed on the cell surface in
response to stress or malignant transformation [11]. Our
study confirms that breast cancer tumor cells show fre-
quent and high expression of NKG2D ligands, as has
been found in other studies for various types of tumors
such as ovarian cancer, colorectal cancer and breast can-
cer [8-10,15,16]. Though all studies show consistently
frequent expression of NKG2D ligands, very diverse
prognostic effects have been described for these types of
ligands in different cancer types [8-10,15,16]. This may
be explained by functional differences in immune regu-
lation for varying expression levels of different ligands
in different environments. Expression of NKG2D ligands
may induce an immune response through binding to the
NKG2D receptor, present on NK cells and a subset of T
cells [11]. Therefore, selective outgrowth of malignant
cells that do not express these NKG2D ligands may be a
mechanism of tumor immune escape. On the other
hand, overexpression of NKG2D ligands could lead to
overstimulation and thereby insensibility or anergy of
immune cells, which would result in evasion of immune
attack by tumors overexpressing NKG2D ligands [11].
Adding to this hypothesis, it has been reported that
NKG2D ligands on the cell membrane may be cleaved
and produce soluble molecules. This shedding of
NKG2D ligands could systemically downregulate
NKG2D receptor expression and thereby result in an
impaired anti-tumor reactivity of NK and T cells
[11,27]. Taken together, the mechanisms by which
NKG2D ligands mediate immune function or dysfunc-
tion may be diverse in different tumors and differ
according to circumstances. The contradictory results
on the prognostic effect of NKG2D ligands found
between different studies on different tumors may be
reflected by the functional and mechanistic implications
of interaction between NKG2D and its ligands. In ovar-
ian cancer expression of NKG2D ligands resulted in a
worse patient outcome, probably due to chronic
MICAB:ULBP2 both low
MICAB:ULBP2 either low
MICAB:ULBP2 both high
Figure 3 Relapses over time related with combined expression of MIC-AB and ULBP-2. X-axis represents patient follow-up in years; Y-axis
represents cumulative relapses in %. Log-rank p-values are shown in the graph. Combined low expression of MIC-AB and ULBP-2 resulted in the
worst outcome of patients concerning relapse-free period (RFP); while combined high expression of both ligands resulted in the most favorable
outcome of patients.
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overexpression and shedding of these ligands, leading to
overstimulation and downregulation of the NKG2D
receptor of NK and T cells and, therefore, an impaired
immune response [10,15]. Supporting the hypothesis
that elevated expression of NKG2D ligands results in
immune escape in ovarian cancer, one study found ele-
vated levels of MIC-AB and ULBP-2 to be positively
correlated to less intra-tumor epithelial CD57+ cells.
The results found in breast cancer in the present study
are contradictory to the results found in ovarian cancer,
Table 3 Cox univariate and multivariable analysis for recurrence free period (RFP) for combined expression of MIC-AB
and ULBP-2.
Relapse Free Period UNIVARIATE MULTIVARIATE
N HR 95% CI p-value HR 95% CI p-value
Age
< 40 48 1.00 0.422
40-50 145 0.97 0.612-1.539
50-60 132 1.17 0.734-1.853
> 60 249 0.90 0.574-1.408
Grade
I 80 1.00 0.001 1.00 0.473
II 282 1.43 0.945-2.172 1.18 0.711-1.948
III 203 2.02 1.326-3.078 1.34 0.802-2.231
Histological type
Ductal 513 1.00 0.291
Other 53 1.24 0.832-1.846
Tumor stage
pT1 211 1.00 < 0.001 1.00 0.298
pT2 272 1.59 1.205-2.093 1.17 0.832-1.637
pT3/4 72 2.49 1.706-3.635 1.45 0.908-2.316
Nodalstage
pN- 307 1.00 < 0.001 1.00 < 0.001
pN+ 250 3.06 2.379-3.945 2.70 1.987-3.669
ER-status
Negative 203 1.00 0.725
Positive 337 1.05 0.808-1.359
PgR-status
Negative 223 1.00 0.744
Positive 313 0.96 0.743-1.236
HER2
No overexpression 378 1.00 0.401
Overexpression 44 1.21 0.776-1.883
Endocrine therapy
ET- 481 1.00 0.197
ET+ 93 1.24 0.896-1.705
Chemotherapy
CT- 444 1.00 0.839
CT+ 130 0.97 0.730-1.291
MIC-AB & ULBP-2
Both Low 68 1.00 < 0.001 1.00 < 0.001
Either one high 275 0.59 0.426-0.820 0.54 0.380-0.757
Both high 64 0.38 0.230-0.612 0.41 0.246-0.682
Missing values are not shown.
Abbreviations N number of patients; HR hazard ratio; 95%CI 95% Confidence Interval; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal
growth factor receptor 2; ET endocrine therapy; CT chemotherapy.
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but similar to those found in colorectal cancer [9,16].
The results in our study and colorectal cancer are sup-
ported by the theory that expression of NKG2D ligands
results in activation of immune cells which is reflected
in a patient beneficial outcome for high ligand expres-
sion [9,16]. We found frequent and high expression of
ligands in our study and statistically significant associa-
tions between expression levels of these ligands, indicat-
ing their cooperation with each other. Adding to the
hypothesis that low expression of these ligands is a
result of selective pressure by the immune system that
results in cancer immune evasion or immunoediting,
low expression of MIC-AB and ULBP-2 were prognostic
factors for an unfavorable RFP of patients. When
expression of MIC-AB and ULBP-2 were combined they
showed to add to each others prognostic effect which is
in line with the results found in previous studies [9,10]
and suggests that NKG2D ligands operate together and
in a similar manner.
Since the exact functioning of all NKG2D ligands and
their cooperative function is largely unknown, we per-
formed outcome analyses with two different variables
that represented combined number of highly co-
expressed ligands and amount of co-expression of all
ligands. The results of these analyses revealed no pat-
terns of any cooperative functioning between all ligands,
as both variables showed no consistent and significant
relationship with clinical outcome of disease. This sug-
gests that the original hypothesis of all NKG2D ligands
having a similar functioning and additive effect on each
other’s functioning in activating or evading an immune
response, may be too simplistic. Considering our results
and those as found in literature, altogether, each
NKG2D ligand analysed separately does not show equal
effects on clinical outcome, and different ligands show
varying prognostic effects in different tumors. Specific
combinations of ligands (e.g. MIC-AB and ULBP-2 in
our study, ULBP2 and ULBP4 in ovarian cancer [10]) do
show additive effects or statistical interactions on prog-
nostic value. However, as highlighted by our combined
analyses, a simple additive effect of all NKG2D ligands,
by considering a similar or cooperative functioning of
all these ligands, can not be assumed. This indicates the
complexity of NKG2D ligands functioning and empha-
sizes the importance of further research on the precise
mechanisms of actions of NKG2D ligands, separately, in
combination with each other, and under different
circumstances.
Conclusions
We have shown in this study, for the first time, that
breast tumors may express all of the known NKG2D
ligands and that expression of MIC-AB and ULBP-2
results in a favorable outcome concerning RFP. A vari-
able combining MIC-AB and ULBP-2 expression has
shown to be a prognostic parameter independently of
known clinicopathological parameters and with high dis-
criminative power. Our results suggest that NKG2D
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Figure 4 Relapses over time related with combined number of NKG2D ligands with high expression (A) and amount of expression of
NKG2D ligands (B). (A) legends in graph show total number of NKG2D ligands with high expression; (B) legends in graph show total intensity
score of all NKG2D ligand expression. X-axis represents patient follow-up in years; Y-axis represents cumulative relapses in %. Log-rank p-values
are shown in the graph. No associations were found with outcome concerning RFP for either combined number of expressed (A) or combined
amount of expression (B) of ligands.
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ligands play a crucial role in tumor immunoediting in
breast cancer and provide further evidence that tumor-
immune interactions play an important role in breast
cancer. In addition, by NKG2D ligand combined ana-
lyses we highlight the importance of further studies on
unraveling the precise separate functioning of these
ligands.
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